Wide Ranks

FBIOP

Fortress Biotech, Inc. - 9.375%

5.20

Top Statistics
Market Cap 27 M Forward PE 0.0000 Revenue Growth -14.30 %
Current Ratio 1.37 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -49.25 % Peg Ratio Dividend Yield 45.96 %
Enterprice / EBITA -1.06 Enterprise / Revenue 1.16 Price To Sales Trailing12 Months 0.3381
Profitability
Profit Margins -49.25 % Operating Margins -168.76 %
Balance Sheet
Total Cash 76 M Total Cash Per Share 3.34 Total Debt 88 M
Total Debt To Equity Current Ratio 1.37 Book Value Per Share 1.49
All Measures
Message Board Id finmb_61731337 Shares Short Prior Month 2155 City Bay Harbor Islands
Uuid 519aaf33-2bcc-3da3-a8c8-568c9fd45fac Previous Close 5.18 First Trade Date Epoch Utc 1 B
Book Value 1.49 Beta 1.75 Total Debt 88 M
Volume 15140 Price To Book 3.49 Fifty Two Week Low 4.86
Total Cash Per Share 3.34 Total Revenue 82 M Shares Short Previous Month Date 1 B
Max Age 86400 Sand P52 Week Change 0.3133 Operating Margins -168.76 %
Last Dividend Value 0.1950 Net Income To Common -49273000 Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 20940 Average Volume10days 20940
Total Cash 76 M Next Fiscal Year End 1 B Revenue Per Share 6.15
Ebitda Margins -109.30 % Dividend Rate 2.34 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 5.18
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.35
Open 5.22 Dividend Yield 45.96 % State FL
Free Cashflow -59199376 Return On Assets -0.3641 Time Zone Short Name EST
Trailing Eps -0.8630 Day Low 5.15 Address1 1111 Kane Concourse
Shares Outstanding 56 M Price Hint 2 Target High Price 0.0000
Website https://www.fortressbiotech.com 52 Week Change -0.5636 Average Volume 19346
Recommendation Key none Forward Eps 0.0000 Compensation As Of Epoch Date 1 B
Quick Ratio 115.00 % Is_sp_500 False Regular Market Day High 5.30
Profit Margins -49.25 % Fifty Two Week High 18.00 Day High 5.30
Shares Short 220 Regular Market Open 5.22 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 1.16 Revenue Growth -14.30 %
Operating Cashflow -98939000 Five Year Avg Dividend Yield 1425.00 % Currency USD
Market Cap 27 M Time Zone Full Name America/New_York Is_nasdaq_100 False
Zip 33154 Quote Type EQUITY Industry Biotechnology
Ex Dividend Date 1 B Regular Market Day Low 5.15 Long Name Fortress Biotech, Inc.
Current Price 5.20 Address2 Suite 301 Enterprise To Ebitda -1.06
Financial Currency USD Current Ratio 1.37 Gross Margins -18.27 %
Industry Disp Biotechnology Country United States Float Shares 16 M
Two Hundred Day Average 11.02 Enterprise Value 96 M Price To Sales Trailing12 Months 0.3381
Forward PE 0.0000 Regular Market Volume 15140 Last Dividend Date 1 B
Ebitda -90308000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States.

The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.

It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea.

The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency.

Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform.

The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015.

Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.